CO6270221A2 - "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea". - Google Patents

"forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".

Info

Publication number
CO6270221A2
CO6270221A2 CO10049269A CO10049269A CO6270221A2 CO 6270221 A2 CO6270221 A2 CO 6270221A2 CO 10049269 A CO10049269 A CO 10049269A CO 10049269 A CO10049269 A CO 10049269A CO 6270221 A2 CO6270221 A2 CO 6270221A2
Authority
CO
Colombia
Prior art keywords
indazol
methylphenyl
fluoro
urea
phenyl
Prior art date
Application number
CO10049269A
Other languages
English (en)
Inventor
Thomas B Borchardt
Alexander Chu-Kung
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO6270221A2 publication Critical patent/CO6270221A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma cristalina 2 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea, maneras para elaborarla, formulaciones que comprenden a la misma y elaboradas con la misma y métodos de tratamiento de pacientes que padecen una enfermedad para usarla. 1.- Forma cristalina 2 de N-[4-(3-amino-1H-indazol-4-il)fenil]-N'-(2-fluoro-5-metilfenil)urea que, cuando se mide a aproximadamente 25°C con radiacion a 1,54178 , se caracteriza por un patron de difraccion en polvo que tiene valores 2? respectivos de aproximadamente 6,7°, 10,1°, 11,8°, 13,4°, 14,4°, 15,4°, 16,6°, 16,8°, 17,8°, 20,5° y 23,4°.
CO10049269A 2007-10-19 2010-04-27 "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea". CO6270221A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98126507P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CO6270221A2 true CO6270221A2 (es) 2011-04-20

Family

ID=40174735

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10049269A CO6270221A2 (es) 2007-10-19 2010-04-27 "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".

Country Status (19)

Country Link
US (1) US7772404B2 (es)
EP (1) EP2195299A1 (es)
JP (1) JP2011500708A (es)
KR (1) KR20100084665A (es)
CN (1) CN101827825B (es)
AU (1) AU2008312534A1 (es)
BR (1) BRPI0818337A2 (es)
CA (1) CA2699356A1 (es)
CO (1) CO6270221A2 (es)
CR (1) CR11444A (es)
DO (1) DOP2010000111A (es)
EC (1) ECSP10010175A (es)
GT (1) GT201000099A (es)
MX (1) MX2010004287A (es)
PA (1) PA8800401A1 (es)
RU (1) RU2010119920A (es)
UA (1) UA99490C2 (es)
WO (1) WO2009052231A1 (es)
ZA (1) ZA201002094B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PT1638941E (pt) * 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
RU2010119920A (ru) 2011-11-27
MX2010004287A (es) 2010-04-30
ZA201002094B (en) 2011-11-30
KR20100084665A (ko) 2010-07-27
AU2008312534A1 (en) 2009-04-23
EP2195299A1 (en) 2010-06-16
WO2009052231A1 (en) 2009-04-23
BRPI0818337A2 (pt) 2017-05-23
PA8800401A1 (es) 2009-05-15
CA2699356A1 (en) 2009-04-23
CR11444A (es) 2010-10-05
CN101827825B (zh) 2012-11-21
DOP2010000111A (es) 2010-07-15
US7772404B2 (en) 2010-08-10
CN101827825A (zh) 2010-09-08
UA99490C2 (en) 2012-08-27
US20090124816A1 (en) 2009-05-14
JP2011500708A (ja) 2011-01-06
ECSP10010175A (es) 2010-06-29
GT201000099A (es) 2012-03-26

Similar Documents

Publication Publication Date Title
CO6270221A2 (es) "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".
DOP2010000112A (es) Productos quimioterapeuticos cristalinos
DOP2010000116A (es) Productos quimioterapeuticos cristalinos
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
UA107561C2 (xx) Поліморфні форми ацилсульфонамідів
UY31407A1 (es) "productos quimioterapéuticos cristalinos"
EA200702590A1 (ru) Ингибиторы растворимой аденилатциклазы
TH104744B (th) สารทางเคมีบำบัดที่เป็นผลึก
UA108849C2 (xx) Кристалічна форма 2-{4-[n-(5,6-дифенілпіразин-2-іл)-n-ізопропіламіно]бутилокси}-n-(метилсульфоніл)ацетаміду
TH104745B (th) สารทางเคมีบำบัดที่เป็นผลึก
ECSP10010177A (es) Productos quimioterapéuticos cristalinos
TH104745A (th) สารทางเคมีบำบัดที่เป็นผลึก

Legal Events

Date Code Title Description
FC Application refused